In February 2016, Utah environmentalist and author Terry Tempest Williams offered to purchase two federal oil and gas leases on property near her home in Southern Utah. Her intention, as stated in a column later appearing in the New York Times, was to keep the resources in the ground “until science finds a way to … More BLM rejects environmentalist offer to buy and hold federal oil and gas leases
An opinion piece at MarketWatch makes a bundle of analytical mistakes as it tries to build the case that persons with conservative political views should prefer the energy policy views of Hillary Clinton over those of Donald Trump. In this case I read the “Clinton” and “Trump” names as a kind of stand-in or representative for … More What energy policies ought conservatives favor–a good example of bad policy analysis
My commentary, “Trump’s policy may undermine pro-growth intentions,” appears in the October 2016 issue of Nature Energy. Here is one of my favorite parts: Trump’s emphasis on energy independence, in North Dakota and elsewhere, has been common among both Republicans and Democrats. President Richard Nixon declared energy independence a priority in an effort to blame the Organization … More On Trump’s energy policy: Big players are bad news for energy policy
As had been announced in June of this year, the Energy and Power subcommittee of the U.S. House of Representatives is devoting some time to a deep look into the Federal Power Act (FPA). At the time of the June announcement the committee sent a letter to Federal Energy Regulatory Commission (FERC) saying: As you know, the … More House Energy and Power Subcommittee takes a look at the Federal Power Act; one small suggestion for reform
Mylan’s price increase of the EpiPen in late August has caused consternation and a lot of debate about the reasons why Mylan has been able to increase the EpiPen price so dramatically above its production cost. Don’t forget that production cost includes the time and resources that comprise FDA compliance costs, even for generics like … More Pharmaceuticals and multi-layered government-granted monopoly
Footnote 16 in Frank Knight’s article, “Cost of production and price over long and short periods,” concluded with a sentence that ought likely to be added at the end of every expert’s policy proposal: Of course this does not mean that they should be required to change quickly to such a basis from the present … More Frank Knight’s footnote on wise social policy
Rather than attempting to “mimic competition,” Giberson suggested simply “to allow competition.” Cost-of-service rate regulation cannot be designed to mimic competition. If you want competitive results, then allow competition. At least that was my claim reported in a Megawatt Daily story, “Texas wires rate study draws mixed reactions.” (From Monday, June 27, 2106; articles are not … More Can regulated rates be designed to mimic competition?